Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
The transcription factor C/EBPalpha (for CCAAT/enhancer binding protein-alpha; encoded by the gene CEBPA) is crucial for the differentiation of granulocytes. Conditional expression of C/EBPalpha triggers neutrophilic differentiation, and no mature granulocytes are observed in Cebpa-mutant mice. Here we identify heterozygous mutations in CEBPA in ten patients with acute myeloid leukemia (AML). We found that five mutations in the amino terminus truncate the full-length protein, but did not affect a 30-kD protein initiated further downstream. The mutant proteins block wild-type C/EBPalpha DNA binding and transactivation of granulocyte target genes in a dominant-negative manner, and fails to induce granulocytic differentiation. Ours is the first report of CEBPA mutations in human neoplasia, and such mutations are likely to induce the differentiation block found in AML.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We have recently shown mutations in the DNA-binding domain of C/EBP␣ in acute myeloid leukemia, suggesting its importance in granulocyte differentiation and leukemia.19”
From Granulocyte inducer C/EBPα inactivates the myeloid master regulator PU.1: possible role in lineage commitment decisions (2002) · cites this paper as [19]
Citations
Cites
The scanning model for translation: an update.
Kozak, M. (1989) · The Journal of cell biology · doi:10.1083/jcb.108.2.229 · Cited by 3,486 · cited 1×
“These findings support the concept that CEBPA forms detected with monospecific antibodies are alternative products translated from several in-frame initiation codons by a leaky ribosome-scanning mechanis”
BackgroundThe Leucine Zipper: A Hypothetical Structure Common to a New Class of DNA Binding Proteins
Landschulz, W. H., Johnson, P. F., & McKnight, S. L. (1988) · Science · doi:10.1126/science.3289117 · Cited by 3,443
Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells.
Cao, Z., Umek, R. M., & McKnight, S. L. (1991) · Genes & Development · doi:10.1101/gad.5.9.1538 · Cited by 1,663
Chromosomal translocations in human cancer
Rabbitts, T. H. (1994) · Nature · doi:10.1038/372143a0 · Cited by 1,503
Descombes, P., & Schibler, U. (1991) · Cell · doi:10.1016/0092-8674(91)90531-3 · Cited by 990
Isolation of a recombinant copy of the gene encoding C/EBP.
Landschulz, W. H., Johnson, P. F., Adashi, E. Y., Graves, B. J., & McKnight, S. L. (1988) · Genes & Development · doi:10.1101/gad.2.7.786 · Cited by 956
Zhang, D.-E., Zhang, P., Wang, N.-D., Hetherington, C. J., Darlington, G. J., & Tenen, D. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.569 · Cited by 910 · cited 1×
“In addition, no mature granulocytes are observed in Cebpa -mutant mice, whereas all the other blood cell types are present in normal proportion”
BackgroundSelf-citationTranscription Factors, Normal Myeloid Development, and Leukemia
Tenen, D. G., Hromas, R., Licht, J. D., & Zhang, D.-E. (1997) · Blood · doi:10.1182/blood.v90.2.489 · Cited by 735 · cited 1×
“gif" NDATA ITEM> ]> Introduction A number of oncogenes that affect proliferation and cell death have been identified in leukemias and other cancers, but relatively few differentiation genes have been implicated in the malignant phenotyp”
BackgroundSelf-citationCCAAT-Enhancer Binding Protein: A Component of a Differentiation Switch
Umek, R. M., Friedman, A. D., & McKnight, S. L. (1991) · Science · doi:10.1126/science.1987644 · Cited by 712 · cited 1×
“bThe abnormalities were one del(9)(q21), one del(9)(q22q34), one t(6;9), one t(10;21)(p11;q22), one del(7)(q22q34), one +8, one +14, and four complex abnormalities.”
BackgroundRadomska, H. S., Huettner, C. S., Zhang, P., Cheng, T., Scadden, D. T., & Tenen, D. G. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.4301 · Cited by 466 · cited 1×
“cThese patients had a 46,XY,del(12)(p11.”
Self-citation
Cited by
Items 601–700 of 930
Perspectives of proteomics in acute myeloid leukemia
Czibere, A. G., Grall, F. T., & Aivado, M. A. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.11.1663 · Cited by 11
Hasemann, M. S., Damgaard, I., Schuster, M. B., Theilgaard‐Mönch, K., Sørensen, A. B., Mršić, A., Krugers, T., Ylstra, B., Pedersen, F. S., Nerlov, C., et al. (2008) · Blood · doi:10.1182/blood-2007-06-097790 · Cited by 11
Leecharendkeat, A., Tocharoentanaphol, C., & Auewarakul, C. U. (2008) · International Journal of Cancer · doi:10.1002/ijc.23796 · Cited by 11
Anastasiadou, E., & Schwaller, J. (2003) · Current Opinion in Hematology · doi:10.1097/00062752-200301000-00007 · Cited by 11
Mutant CEBPA promotes tolerance to inflammatory stress through deficient AP-1 activation
Cadefau-Fabregat, M., Martínez-Cebrián, G., Lorenzi, L., Weiss, F. D., Frank, A.-K., Castelló-García, J. M., Julià-Vilella, E., Gámez-García, A., Yera, L., de Castro, C. P. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58712-7 · Cited by 11
“In AML, CEBPA mutations can be grouped into two main classes: frameshift mutations at the N-terminal region of the gene result in the exclusive translation of the short isoform p30, while in-frame mutations within the C-terminal bZIP domain compromise DNA binding and dimerization 30,31 .”
Tetrahedral framework nucleic acids: Nanokeys unlocking a new era of precision biomedicine
He, Z., Liu, Y., Chen, Y., Zhang, Y., Zhang, Y., Chen, Z., Bao, D., Yang, W., & Liu, H. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.10.052 · Cited by 11
Germline Predisposition to Myeloid Neoplasms
Obiorah, I. E., Upadhyaya, K., & Calvo, K. R. (2023) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2023.06.004 · Cited by 10
Regulation and deregulation of mRNA translation during myeloid maturation
Khanna‐Gupta, A. (2010) · Experimental Hematology · doi:10.1016/j.exphem.2010.10.011 · Cited by 10
“It has been demonstrated that the p30 C/EBPa protein not only interferes with the DNA binding ability of p42 C/EBPa, thus inhibiting transactivation of key granulocytic target genes in a dominant-negative manner [30], but also binds to the promoters of a distinctive set of target genes to alter their transcription [31…”
Molecular landscape in acute myeloid leukemia: where do we stand in 2016
Al-Issa, K., & Aziz, N. (2016) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0061 · Cited by 10
Nie, Y., Su, L., Li, W., & Gao, S. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103379 · Cited by 10
Molecular cloning and preliminary analysis of the human α-methylacyl-CoA racemase promoter
Chen, W., Wu, W., Zhao, J., Yu, C., Liu, W., Jiang, A., & Zhang, J. (2007) · Molecular Biology Reports · doi:10.1007/s11033-007-9196-x · Cited by 12
“Mutations in the C/EBPa gene were found in a subclass of acute human myeloid leukemias [22].”
Dependence on Myb expression is attenuated in myeloid leukaemia with N-terminal CEBPA mutations
Volpe, G., Cauchy, P., Walton, D. S., Ward, C., Blakemore, D., Bayley, R., Clarke, M. L., Schmidt, L., Nerlov, C., García, P., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201800207 · Cited by 10
“…classi fi ed into two major groups: (i) C-terminal insertions or deletions within the basic region leucine zipper DNA-binding domain; and (ii) N-terminal mutations that lead to the complete ablation of p42 while retaining normal p30 function (Pabst et al, 2001; Leroy et al, 2005; Fasan et al, 2014).”
Xu, Z., Meng, S., Bai, J., Sun, C., Zhao, L., Tang, R., Yin, Z., Ji, J., Yang, W., & Ma, G. (2019) · Current Cancer Drug Targets · doi:10.2174/1568009619666190912161003 · Cited by 10
Wang, Q., Wang, R., Feng, B., Li, S., Mahboob, S., & Shao, C. (2020) · Gene · doi:10.1016/j.gene.2020.145321 · Cited by 10
Ranjan, R., Thompson, E. A., Yoon, K., & Smart, R. C. (2009) · Oncogene · doi:10.1038/onc.2009.176 · Cited by 12
“Consistent with its role in the regulation of differentiation, C/EBPα has been shown to be a tumor suppressor gene in acute myeloid leukemia where it is inactivated in ∼9% of AML cases through specific somatic mutations (Pabst et al., 2001; Gombart et al., 2002).”
Backgroundv-Myc inhibits C/EBPβ activity by preventing C/EBPβ-induced phosphorylation of the co-activator p300
Steinmann, S., Schulte, K., Beck, K., Chachra, S. S., Bujnicki, T., & Klempnauer, K.-H. (2009) · Oncogene · doi:10.1038/onc.2009.90 · Cited by 10
Fuchs, O., Kostečka, A., Provazníková, D., Krasna, B., Kotlín, R., Staňková, M., Kobylka, P., Dostálová, G., Zeman, M., & Chochola, M. (2010) · Folia Biologica · doi:10.14712/fb2010056020051 · Cited by 10
Almaghrabi, R. O. M., Alyahyawi, Y., Keane, P., Mian, S. A., Habel, K., Atkinson, A., Ward, C., Bayley, R., Sargas, C., Menéndez, P. R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60192-8 · Cited by 10
Extracellular vesicles as the drug delivery vehicle for gene-based therapy
Aquino, A. D., Rubinstein, A., Кудрявцев, И. В., Yakovlev, A. A., & Головкин, А. С. (2025) · Applied Physics Reviews · doi:10.1063/5.0255519 · Cited by 10
Riccio, F., Micarelli, E., Secci, R., Giuliani, G., Vumbaca, S., Massacci, G., Castagnoli, L., Fuoco, C., & Cesareni, G. (2022) · Cell Death Discovery · doi:10.1038/s41420-021-00811-7 · Cited by 10
“The differentiation steps are regulated by a complex interplay among numerous transcription factors [18].”
BackgroundOf drills and bones: Giovanni Ghedini and the origin of bone marrow biopsy
Pizzi, M., Binotto, G., Savioli, G. R., Tos, A. P. D., & Orazi, A. (2022) · British Journal of Haematology · doi:10.1111/bjh.18206 · Cited by 9
Wang, H., Luo, G., Hu, X., Xu, G., Wang, T., Liu, M., Qiu, X., Li, J., Fu, J., Feng, B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37381-4 · Cited by 9
Ribosome rescue factor PELOTA modulates translation start site choice for C/EBPα protein isoforms
Fernandez, S. G., Ferguson, L., & Ingolia, N. T. (2024) · Life Science Alliance · doi:10.26508/lsa.202302501 · Cited by 9
Fos, J., Pabst, T., Petkovic, V., Ratschiller, D., & Mueller, B. U. (2011) · Blood · doi:10.1182/blood-2010-11-320747 · Cited by 11
Self-citationProteomic approaches in myeloid leukemia
Kanaujiya, J. K., Lochab, S., Pal, P., Christopeit, M., Singh, S. M., Sanyal, S., Behre, G., & Trivedi, A. K. (2011) · Electrophoresis · doi:10.1002/elps.201000428 · Cited by 9
Self-citationInhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells
Chlebowska, J., Sokołowska, O., Gaj, P., Łaźniewski, M., Firczuk, M., Borowiec, K., Sas‐Nowosielska, H., Bajor, M., Malinowska, A., Muchowicz, A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.190231 · Cited by 9
Dual DNA and protein tagging of open chromatin unveils dynamics of epigenomic landscapes in leukemia
Lee, J. D., Paulo, J. A., Posey, R. R., Mugoni, V., Kong, N. R., Cheloni, G., Lee, Y.-R., Slack, F. J., Tenen, D. G., Clohessy, J. G., et al. (2021) · Nature Methods · doi:10.1038/s41592-021-01077-8 · Cited by 9
Self-citationBouvier, A., Hamel, J., Delaunay, J., Delabesse, É., Dumas, P., Ledoux, M., Péterlin, P., Luquet, I., Guépin, G. R., Bulabois, C., et al. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13626 · Cited by 9
“Cluster 5 CEBPA biallelic mutations 17 (6) CEBPAdm (100), CEBPAsm (53) Cluster 6 NPM1− FLT3ITD− with epigenetic mutations 43 (14) IDH2- R172 (82), ASXL1 (74), IDH2 (55), IDH1 (40), CEBPAsm (28), DNMT3A (22)”
Wang, T., Hua, H., Wang, Z., Wang, B., Cao, L., Qin, W., Pin, W., Cai, X., Chao, H., & Lu, X. (2022) · Hematology · doi:10.1080/16078454.2022.2103964 · Cited by 9
Novel Mutations in CEBPA in Korean Patients with Acute Myeloid Leukemia with a Normal Karyotype
Kim, S., Kim, D., Jang, J., Jung, C.-W., Jang, M., Ki, C., Kim, J., Kim, S., & Kim, H. (2012) · Annals of Laboratory Medicine · doi:10.3343/alm.2012.32.2.153 · Cited by 9
“org rable to the frequency reported in previous studies on other ethnic groups [20-24].”
ResultProteomics approaches for myeloid leukemia drug discovery
Kapoor, I., Pal, P., Lochab, S., Kanaujiya, J. K., & Trivedi, A. K. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.724055 · Cited by 9
“Although C/EBPa p30 acts as a dominant negative inhibitor of wild-type C/EBPa (p42); its mechanism of action is poorly understood [48].”
BackgroundShen, X., Sun, N.-N., Yin, Y., Liu, S., Liu, X., Peng, H., Dai, C.-W., Xu, Y., Deng, M., Luo, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7072 · Cited by 11
“1 and microRNAs), and mutations of C/EBPA have been observed in about 10% of patients with acute myeloid leukemia (AML) [27, 28].”
BackgroundMendoza, H., Chen, P., Pine, A. B., Siddon, A. J., Bale, A. E., Gowda, L., Killie, A., Richards, J. L., Varin-Tremblay, C., Kloss, R. A., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1861276 · Cited by 9
Molecular pathogenesis of acute myeloid leukemia: A diverse disease with new perspectives
Thol, F. R., & Ganser, A. (2010) · Frontiers of Medicine · doi:10.1007/s11684-010-0220-5 · Cited by 9
Hassan, S., & Smith, M. (2014) · Hematology · doi:10.1179/1024533214z.000000000312 · Cited by 10
CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis
Awad, M. M., Aladle, D. A., Abousamra, N. K., Elghannam, D. M., & Fawzy, I. M. (2013) · Hematology · doi:10.1179/1607845412y.0000000032 · Cited by 9
Shimokawa, T., Nunomura, S., Fujisawa, D., & Ra, C. (2013) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2013.09.004 · Cited by 10
Juhl‐Christensen, C., Bomberg, M., Melsvik, D., Hokland, P., & Nyvold, C. G. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01117.x · Cited by 9
Kagita, S., Uppalapati, S., Gundeti, S., & Digumarti, R. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv064 · Cited by 9
Emerging molecular predictive and prognostic factors in acute myeloid leukemia
McCurdy, S. R., & Levis, M. J. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1393669 · Cited by 12
Fioretos, T., & Johansson, B. (2010) · Wiley eBooks · doi:10.1002/9781118010136.ch7 · Cited by 11
Molecular biology in acute leukemia
Camós, M., & Colomer, D. (2006) · Clinical & Translational Oncology · doi:10.1007/s12094-006-0060-6 · Cited by 9
Pathobiology of Acute Myeloid Leukemia
Brunner, A. M., & Graubert, T. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00058-5 · Cited by 9
Structural basis for specific DNA sequence recognition by the transcription factor NFIL3
Chen, S., Lei, M., Liu, K., & Min, J. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.105776 · Cited by 9
Schnittger, S., Bacher, U., Eder, C., Lohse, P., Haferlach, C., Kern, W., & Haferlach, T. (2010) · Experimental Hematology · doi:10.1016/j.exphem.2010.09.009 · Cited by 8
“They are strongly associated with a normal karyotype and have been shown to confer a favorable prognostic impact in adult [13–17] and in pediatric patients [18].”
BackgroundSelf-citationClinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia
Ahn, S., Kim, T., Kim, M., Song, G., Jung, S., Yang, D., Lee, J., Kim, M. Y., Jung, C. W., Jang, J., et al. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2022.1407 · Cited by 8
CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment
Tien, F., & Hou, H. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03773-5 · Cited by 8
Zhu, J., Zhu, X., Shi, C., Li, Q., Jiang, Y., Chen, X., Sun, P., Jin, Y., Wang, T., & Chen, J. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03457-4 · Cited by 8
Ahmad, F., Rajput, S., Mandava, S., & Das, B. R. (2012) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2011.0317 · Cited by 8
C/EBPα in leukemogenesis: Identity and origin of the leukemia‐initiating cell
Schuster, M. B., & Porse, B. T. (2009) · BioFactors · doi:10.1002/biof.36 · Cited by 8
Xue, M., LI, X., & Chen, W. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3563 · Cited by 8
Tumor Suppressor Genes in Myeloid Differentiation and Leukemogenesis
Britschgi, C., & Fey, M. F. (2009) · Future Oncology · doi:10.2217/14796694.5.2.245 · Cited by 8
Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer
Marinescu, G., & Feng, Y. (2026) · Molecular Oncology · doi:10.1002/1878-0261.70241 · Cited by 7
Rücker, F. G., Corbacioglu, A., Krzykalla, J., Cocciardi, S., Lengerke, C., Germing, U., Wulf, G. G., Samra, M. A., Teichmann, L. L., Lübbert, M., et al. (2024) · HemaSphere · doi:10.1002/hem3.123 · Cited by 7
Nemo‐like kinase blocks myeloid differentiation by targeting tumor suppressor C/ EBPα in AML
Singh, A. K., Thacker, G., Upadhyay, V., Mishra, M., Sharma, A., Sethi, A., Chowdhury, S., Siddiqui, S. I., Verma, S. P., Pandey, A., et al. (2024) · FEBS Journal · doi:10.1111/febs.17245 · Cited by 7
Molecular Analysis of Gene Rearrangements and Mutations in Acute Leukemias and Myeloid Neoplasms
Sholl, L. M., Longtine, J. A., & Kuo, F. C. (2017) · Current Protocols in Human Genetics · doi:10.1002/cphg.31 · Cited by 7
“CEBPA mutations are associated with an improved outcome in patients with NK-AML; however, akin to NPM1, the presence of a concurrent FLT3-ITD is an unfavorable finding (Leroy et al., 2005).”
BackgroundInfluentialOptimizing homeostatic cell renewal in hierarchical tissues
Alvarado, C., Fider, N. A., Wearing, H. J., & Komarova, N. L. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005967 · Cited by 8
Zhu, R., Lin, W., Tang, L. V., & Hu, Y. (2021) · Aging · doi:10.18632/aging.202493 · Cited by 7
Acute myeloid leukemia due to germline CEBPA mutation in a Syrian family
Wafa, A., Ali, B., Moassass, F., Kheder, M., Aljapawe, A., Al‐Halabi, B., Mrasek, K., Liehr, T., & Al‐Achkar, W. (2022) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1854 · Cited by 7
“However, CEBPA gene mutations are also observed in 10– 15% of “common” AML cases, mostly in the context of a normal karyotype, and are associated with a favorable outcome (Pabst et al., 2001; Renneville et al., 2009; Green et al., 2010; Dufour et al., 2010).”
BackgroundK313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML)
Carnicer, M. J., Lasa, A., Buschbeck, M., Serrano, E., Carricondo, M., Brunet, S., Aventin, A. M., Sierra, J., Croce, L. D., & Nomdedeu, J. F. (2008) · Annals of Hematology · doi:10.1007/s00277-008-0528-2 · Cited by 10
Detection of CEBPA Double Mutants in Acute Myeloid Leukemia Using a Custom Gene Expression Array
van Vliet, M. H., Burgmer, P., de Quartel, L., Brand, J., de Best, L., Viëtor, H. E., Löwenberg, B., Valk, P. J. M., & van Beers, E. H. (2013) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2012.0437 · Cited by 7
“…(CEBPA) encodes a transcription factor that has been found to play a critical role in granulopoiesis and is mutated in 5%–14% of patients with AML (Pabst et al., 2001; Gombart et al., 2002; Preudhomme et al., 2002; Snaddon et al., 2003; van Waalwijk van Doorn-Khosrovani et al., 2003; Fröhling…”
BackgroundMannelli, F., Ponziani, V., Bonetti, M. I., Bencini, S., Cutini, I., Gianfaldoni, G., Scappini, B., Pancani, F., Rondelli, T., Benelli, M., et al. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.06.003 · Cited by 7
Mi, L., Hu, K., Wen, X., Sun, J. P., Wu, A., Wang, M., Zheng, M., Zang, L., & Ji, J. (2018) · Europe PMC (PubMed Central) · Cited by 8
An updated account on molecular heterogeneity of acute leukemia.
Rahul, E., Goel, H., Chopra, A., Ranjan, A., Gupta, A. K., Meena, J. P., Bakhshi, S., Misra, A., Hussain, S., Viswanathan, G. K., et al. (2021) · American Journal of Blood Research · Cited by 8
Veiga, D. F. T., Tremblay, M. R., Gerby, B., Herblot, S., Haman, A., Gendron, P., Lemieux, S., Zúñiga‐Pflücker, J. C., Hébert, J., Cohen, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867443 · Cited by 7
“Master regulators of hematopoietic lineages have been implicated in tumor suppressor function, as reported for C/ EBPa (108, 109) and SPI1/PU.1 in acute myeloblastic leukemia (AML) (110) or PAX5 loss of function in B-ALL (90, 111).”
BackgroundRubnitz, J. E., Razzouk, B. I., & Ribeiro, R. C. (2006) · Cambridge University Press eBooks · doi:10.1017/cbo9780511471001.020 · Cited by 8
Adult-onset hereditary myeloid malignancy and allogeneic stem cell transplantation
Toya, T., Harada, H., Harada, Y., & Doki, N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.997530 · Cited by 7
“N-terminal mutations are known to generate p30 isoforms, which have dominant negative effect (46).”
BackgroundGranulocytopoiesis and Monocytopoiesis
Khanna‐Gupta, A., & Berliner, N. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00027-5 · Cited by 9
Styryl Quinazolinones as Potential Inducers of Myeloid Differentiation via Upregulation of C/EBPα
Radhakrishnan, S., Takei, H., Syed, R., Kobayashi, I. S., Hui, L. B., Kamal, Ä., Tenen, D. G., & Kobayashi, S. S. (2018) · Molecules · doi:10.3390/molecules23081938 · Cited by 7
Self-citationZhang, Z., Xu, Y., Jiang, M. P., Kong, F., Chen, Z., Liu, S., & Li, F. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1702398 · Cited by 7
Wang, X., Yu, H., Zou, W.-B., Mi, C., Dai, G., Zhang, T., Zhang, G., Xie, K., & Wang, J.-Y. (2020) · Genes · doi:10.3390/genes11050476 · Cited by 7
Adult Stem Cel Diferentiation and Trafficking And Their Implications in Disease
Zhuge, Y., Liu, Z., & Velazquez, O. C. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-7037-4_12 · Cited by 7
Epigenetic regulation of tumor suppressors in t(8:21)-containing AML
Yang, G., Khalaf, W. F., van de Locht, L. T., Jansen, J. H., van der Reijden, B. A., Müller‐Tidow, C., Delwel, R., Serve, H. L., Clapp, D. W., & Hiebert, S. W. (2004) · Annals of Hematology · doi:10.1007/s00277-003-0841-8 · Cited by 7
Lu, S., Liu, J., Chen, S., Li, B., & Ye, Z. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189489 · Cited by 6
Molecular Targets in Myelodysplastic Syndromes
Hofmann, W., & Nolte, F. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.07.015 · Cited by 6
Up a lymphoid blind alley: Does CALM/AF10 disturb Ikaros during leukemogenesis?
Greif, P. A., & Bohlander, S. K. (2011) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v2.i6.115 · Cited by 8
Mannelli, F., Bencini, S., Piccini, M., Gianfaldoni, G., Bonetti, M. I., Peruzzi, B., Caporale, R., Scappini, B., Pancani, F., Ponziani, V., et al. (2020) · Cancers · doi:10.3390/cancers12113196 · Cited by 6
Mutations in the runt homology domain of CBFα2 in myeloid malignancies with acquired trisomy 21
Snaddon, J., Neat, M. J., Fitzgibbon, J., Smith, M. L., Rohatiner, A. Z. S., Lister, T. A., & Amess, J. A. L. (2002) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(02)00525-3 · Cited by 6
de la Blétière, D. R., Blanchet, O., Cornillet‐Lefèbvre, P., Coutolleau, A., Baranger, L., Geneviève, F., Luquet, I., Hunault, M., Beucher, A., Schmidt, A., et al. (2012) · BMC Medical Genomics · doi:10.1186/1755-8794-5-6 · Cited by 6
“Regarding NKAMLs and in agreement with previous reports, the highest median confidence levels were observed for NKAMLs with mutated NPM1 and the lowest ones for NKAMLs with neither NPM1 nor FLT3 mutations (additional file 1, Figure S3) [22-26].”
BackgroundResultMiyashita, N., Onozawa, M., Yoshida, S. Y., Kimura, H., Takahashi, S., Yokoyama, S., Matsukawa, T., Hirabayashi, S., Fujisawa, S., Mori, A., et al. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03567-1 · Cited by 6
Bachelot, A., Bouvier, A., Riou, J., Thépot, S., Giltat, A., Gomes, C. N., Paillassa, J., Jouanneau‐Courville, R., Renard, M., Beucher, A., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.26917 · Cited by 6
Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML
Borate, U., Absher, D., Erba, H. P., & Pasche, B. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.116 · Cited by 7
The Etiology of Acute Leukemia
Nichol, J. N., Assouline, S. E., & Miller, W. H. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_14 · Cited by 7
Kimura, Y., Iwanaga, E., Iwanaga, K., Endo, S., Inoue, Y., Tokunaga, K., Nagahata, Y., Masuda, K., Kawamoto, H., & Matsuoka, M. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13551 · Cited by 6
CEBPA Gene Mutational Status: A Complete Screening Using High-Resolution Melt Curve Analysis
Rázga, F., Dvořáková, D., Jurřček, T., Ježíšková, I., Křístková, Z., & Mayer, J. (2009) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256325 · Cited by 6
Jakubowiak, A. J., Cammenga, J., Sokolic, R. A., Álvarez, S., Jackson, G., Hedvat, C. V., & Nimer, S. D. (2000) · Current Oncology Reports · doi:10.1007/s11912-000-0083-z · Cited by 8
GATA1 - A Player in Normal and Leukemic Megakaryopoiesis
Hitzler, J. K. (2002) · Pediatric Research · doi:10.1203/00006450-200212000-00003 · Cited by 6
A review of C/EBP α: a potential novel target for solid tumor intervention
Li, X., Dai, T., Zhao, J., Liang, Y., Chen, L., Chen, C., Guo, M., Han, Y., Xu, L., & Zhao, J. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06884-7 · Cited by 6
Hematolymphoid neoplasms: World Health Organization versus rest of the world
Gujral, S. (2008) · Leukemia · doi:10.1038/leu.2008.327 · Cited by 5
Blau, O. (2015) · InTech eBooks · doi:10.5772/60928 · Cited by 7
Guolo, F., Minetto, P., Clavio, M., Marcolin, R., Miglino, M., Passannante, M., Caviglia, F., Ballerini, F., Tedone, E., Kunkl, A., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1737685 · Cited by 5
Odaira, K., Yasuda, T., Okada, K., Shimooka, T., Kojima, Y., Noura, M., Tamura, S., Kurahashi, S., Iwamoto, E., Sanada, M., et al. (2022) · Cancer Science · doi:10.1111/cas.15641 · Cited by 5
Wouters, B. J., Koss, C., & Delwel, R. (2007) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.10.006 · Cited by 5
Head, D., & Thompson, M. A. (2007) · Springer eBooks · doi:10.1007/978-3-540-72304-2_2 · Cited by 6
Aly, R., Taalab, M. M., & Abdsalam, E. M. (2015) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000567 · Cited by 5
Kansal, R. (2020) · Journal of Clinical Haematology · doi:10.33696/haematology.1.006 · Cited by 5
“described mutations in AML in the CEBPA gene, which encodes for the transcription factor CEBPA, crucial for granulocytic differentiation [34].”
BackgroundYusoff, Y. M., Ahid, F., Seman, Z. A., Abdullah, J., Kamaluddin, N. R., Esa, E., & Zakaria, Z. (2021) · Molecular Cytogenetics · doi:10.1186/s13039-021-00561-2 · Cited by 5
Kansal, R. (2021) · Journal of Hematology Research · doi:10.12974/2312-5411.2021.08.3 · Cited by 5
GENETIC PREDISPOSITION TO HEMATOLOGIC MALIGNANCIES IN CHILDHOOD AND ADOLESCENCE
Fabozzi, F., & Mastronuzzi, A. (2023) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2023.032 · Cited by 5
“12,13 It has been shown that nearly 10% of these cases also carry a germline CEBPA mutation, typically a frameshift or nonsense mutation near the amino terminus of the encoded protein.”
BackgroundDifferentiation or leukemia: Is C/EBPα the answer?
Hiebert, S. W. (2001) · Nature Medicine · doi:10.1038/86461 · Cited by 7
Metadata
- Authors
- Pabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., & Tenen, D. G.
- Affiliations
- Harvard University (US)
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Tenen, Daniel G.
- Venue
- Nature Genetics
- Published
- 2001-03
- Volume
- 27
- Issue
- 3
- Pages
- 263-270
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2100088478
- Cited by
- 901
- References
- 33
- Citations by year
- 2026: 15 · 2025: 11 · 2024: 23 · 2023: 21 · 2022: 30 · 2021: 22 · 2020: 27 · 2019: 17 · 2018: 22 · 2017: 27 · 2016: 29 · 2015: 47 · 2014: 37 · 2013: 34 · 2012: 50
- FWCI
- 23.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL056745, HL56745)
- National Cancer Institute (CA-72009, P01CA072009)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Blood disorders and treatments
- Keywords
- CEBPA, C/EBPα, acute myeloid leukemia, dominant negative mutation, heterozygous mutation, transcription factors, granulocytic differentiation, DNA binding, transcriptional activation, N-terminal truncation
- MeSH terms
- Base Sequence, Cell Differentiation, Cell Nucleus, DNA, Neoplasm, Genes, Dominant, Granulocytes, Heterozygote, Humans, Mutation, Neutrophils, Leukemia, Myeloid, Acute, Transcriptional Activation, Sequence Deletion, DNA Primers, CCAAT-Enhancer-Binding Protein-alpha, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.